The New ERISA Risk: What Self-Funded Employers Can Do to Protect Themselves
ERISA Readiness Is a Management System, Not a Search for the Lowest Price
Healthcare price transparency has made variation easier to see. A service negotiated at one rate may be available through another network at a materially lower rate, even when the hospital and clinical team are the same. For employers responsible for self-funded health benefits, that visibility creates a difficult question: once a cost difference can be found, what process is required to act prudently on it?
The answer is not simply to select the cheapest option. ERISA fiduciary risk turns on how benefit decisions are made, monitored, and documented. A strong defense is built through governance: clear authority, credible information, disciplined vendor oversight, and an evidence trail showing that the organization investigated material risks and made reasoned decisions.
The process can matter as much as the result
ERISA’s fiduciary framework centers on duties of loyalty and prudence. In practical terms, decision-makers should act in participants’ interests and follow a careful process when selecting and managing plan services.
That does not mean every decision must produce the lowest possible claim. Networks vary in access, quality controls, geographic reach, member experience, and operational support. A lower case rate may exclude pre-procedure evaluation, complications, travel, or post-acute care. The relevant question is whether the organization considered the factors that materially affect value and can show how it reached the decision.
This distinction is crucial because outcomes are uncertain. A prudent decision can still produce a costly case. An imprudent process can occasionally produce a favorable one. Governance creates defensibility when the outcome alone cannot explain whether the organization fulfilled its responsibility.
Delegation does not eliminate accountability
Self-funded employers rely on third-party administrators, pharmacy benefit managers, brokers, consultants, specialty networks, and point-solution vendors. Those partners are necessary, but contracting with them does not end the employer’s oversight obligation.
The organization should know which party has discretion, what information it can access, how compensation works, and where incentives may conflict. A contract may state that a vendor is not a fiduciary, yet operational authority still matters. If a party exercises discretion over plan assets or decisions, the practical relationship may deserve closer legal review than the label suggests.
Vendor management should therefore be continuous rather than episodic. At renewal, the plan should review performance, fees, conflicts, network value, data access, and alternatives. During the contract, it should monitor material variances, request supporting information, and document unanswered questions. A vendor’s reluctance to provide data is itself information that belongs in the governance record.
Broker compensation deserves similar attention. Direct fees, commissions, bonuses, and other economic relationships can affect recommendations. The objective is not to assume misconduct. It is to understand incentives well enough to evaluate advice independently.
Price variation becomes a governance trigger
Transparent data can expose a large difference without explaining it. The webinar uses a pediatric heart-transplant example at the same hospital and with the same physicians: one network rate was approximately $360,000, while a specialty-network rate was about $195,000. Another comparison involved a difference of more than $300,000 for a liver transplant.
Those figures should not be treated as universal savings. They demonstrate why high-cost, high-variation categories merit investigation. A benefits committee that discovers a significant spread should ask what each price includes, whether the networks are comparable, how outcomes are measured, what access constraints exist, and what implementation would require.
This creates a practical hierarchy for oversight. Start with categories where spend is high, price dispersion is large, and vendor incentives are difficult to understand. Transplants, specialty pharmacy, out-of-network claims, complex surgeries, and certain facility services may warrant deeper review than categories with limited financial exposure.
That means the governance standard is “show that the alternative was evaluated with appropriate diligence.”
Remote work expands the exposure surface
A geographically dispersed workforce can encounter more out-of-network care, local price variation, fragmented provider relationships, and inconsistent navigation. A network strategy designed for a concentrated employee base may not remain adequate when members live across many markets.
Employers should examine access and cost by geography, not only at the national aggregate. That includes identifying where employees lack high-quality in-network options, where specialty services produce meaningful variation, and whether navigation support can direct members to better-value care without creating unreasonable burdens.
The member experience matters because a theoretically superior network has little value if it is difficult to use. Communications, travel benefits, scheduling help, continuity of care, and clinical appropriateness must be included in the evaluation. Prudence is demonstrated through a complete decision, not a spreadsheet that isolates price.
Build a six-part evidence trail
An employer can strengthen readiness through a repeatable operating model:
Map authority. Identify the internal committees, executives, and vendors that make or influence discretionary decisions.
Inventory material spend. Prioritize categories with high cost, significant variation, or opaque incentives.
Request evidence. Obtain fee disclosures, network comparisons, performance data, contract terms, and alternative options.
Deliberate formally. Record the factors considered, questions asked, advice received, and reasons for the final decision.
Monitor performance. Establish a cadence for reviewing cost, quality, access, member experience, and vendor compliance.
Escalate exceptions. Define what happens when data are withheld, performance falls short, or a conflict emerges.
The evidence trail should be usable, not ceremonial. Meeting minutes that record only a final vote provide less protection than a concise summary of the decision logic. Vendor reports should be challenged where assumptions are unclear. Benchmarking should use comparable populations and complete episodes of care.
This process also improves management even when litigation never occurs. It can surface redundant vendors, weak contracts, avoidable variation, and benefits that no longer fit the workforce.
Readiness requires legal partnership, not legal ownership
ERISA risk is legal, but the controls are operational. Counsel can interpret fiduciary obligations, assess discretionary authority, and review litigation developments. Benefits, finance, procurement, and human resources teams must implement the governance process in daily work.
That division of labor matters. Waiting for legal review at renewal does not replace year-round monitoring. Conversely, operational teams should not make legal conclusions from headlines or isolated cases. The most effective model combines legal guidance with clear management routines and complete records.
Price transparency has changed what employers can know. Litigation has increased the consequences of failing to investigate. The response should be neither panic nor a race to the cheapest vendor. It should be a disciplined system that can demonstrate who decided, what they knew, what they asked, and why the decision was reasonable for plan participants.
About the Speakers
Tim Michaels
CEO of HealthRate
Tim is the CEO of HealthRate, where he leads the development of healthcare analytics, financial forecasting, and risk-based solutions for at-risk healthcare organizations. He previously served as Senior Vice President of Insurance Risk Services at Emerging Therapy Solutions and has extensive experience building companies, developing risk-based products, and advising healthcare organizations. Connect with Tim on LinkedIn.
Demi Radeva, MSc
Founder and Chief Strategist at Akros Advisory
Demi has more than a decade of experience across Medicaid, Medicare, and Commercial health plans, including leadership roles at UnitedHealthcare and Optum. She now advises HealthTech companies on reimbursement, payer strategy, market access, and commercialization. Connect with Demi on LinkedIn.
Comments